Gilead Sciences Inc. closed 0.11% below its 52-week high of $112.11, which the company reached on February 25th.
The Juilliard-trained talent said he's honored to get the gig: "Our queer siblings across the country who are being unfairly ...
Seattle's Nautilus Biotechnology is laying off 16% of workforce, and plans to release its commercial platform in late 2026.
David Furnish’s leadership at EJAF proves brands can do more than raise awareness —they can dismantle stigma and drive ...
Gilead Sciences' Q4 2024 results, driven by HIV drug demand and Trodelvy growth, make it a compelling choice for long-term ...
A common CV risk factor calculator for patients with HIV underestimates risk for Black patients and women, while risk for ...
Additional data from CheckMate 274 showed that adjuvant nivolumab benefits patients with muscle-invasive bladder cancer with ...
From breakthrough treatments to AI-driven diagnostics, healthcare is evolving faster than ever. With increasing healthcare ...
We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...
Learn more about whether Gilead Sciences, Inc. or Insmed Incorporated is a better investment based on AAII's A+ Investor ...
Investors with a lot of money to spend have taken a bullish stance on Gilead Sciences GILD. And retail traders should know. We noticed this today when the positions showed up on publicly available ...